Synthesis and Preliminary Evaluation of the Antimicrobial Activity of Selected 3-Benzofurancarboxylic Acid Derivatives

Jerzy Kossakowski 1, Mariola Krawiecka 1,*, Bożena Kuran 1, Joanna Stefańska 2 and Irena Wolska 3

1 Department of Medical Chemistry, Medical University of Warsaw, 3 Oczki Str., 02-007 Warsaw, Poland; E-Mails: jerzy.kossakowski@wum.edu.pl (J.K.); bozena.kuran@wum.edu.pl (B.K.)
2 Department of Pharmaceutical Microbiology, Medical University of Warsaw, 3 Oczki Str., 02-007 Warsaw, Poland; E-Mail: joanna.stefanska@wum.edu.pl (J.S.)
3 Department of Crystallography, Faculty of Chemistry, Adam Mickiewicz University, 6 Grunwaldzka Str., 60-780 Poznań, Poland; E-Mail: iwolska@amu.edu.pl (I.W.)

* Author to whom correspondence should be addressed; E-Mail: mariola.krawiecka@wum.edu.pl.

Received: 1 June 2010; in revised form: 29 June 2010 / Accepted: 1 July 2010 / Published: 6 July 2010

Abstract: Halogen derivatives of selected 3-benzofurancarboxylic acids were prepared using 6-acetyl-5-hydroxy-2-methyl-3-benzofuranocarboxylic acid as starting material. 1H-NMR spectra were obtained for all of the synthesized structures, and for compound VI, an X-ray crystal structure was also obtained. All derivatives were tested for antimicrobial activity against a selection of Gram-positive cocci, Gram-negative rods and yeasts. Three compounds, III, IV, and VI, showed antimicrobial activity against Gram-positive bacteria (MIC 50 to 200 µg/mL). Compounds VI and III exhibited antifungal activity against the Candida strains C. albicans and C. parapsilosis (MIC – 100 µg/mL).

Keywords: 3-benzofurancarboxylic acid; antimicrobial activity; antifungal activity; X-ray diffraction

1. Introduction

It is well known that many of heterocyclic compounds containing oxygen display important biological properties such as antiarrhythmic, spasmolitic, antiviral, anticancer, antifungal and anti-inflammatory activity [1–7]. This group of compounds includes the furobenzopyranone, benzofuran,
and benzopyranone systems. Good examples of the above mentioned are the drugs amiodarone, benziodarone and benzbromarone (Figure 1).

**Figure 1.** The structures of amiodarone, benzbromarone and benziodarone.

![Chemical structures of amiodarone, benzbromarone, and benziodarone](image)

Amiodarone is used clinically as an antiarrhythmic agent causing alternations in calcium homeostasis, and cell death in yeasts and it also possesses antifungal activity [1,8–11]. Benziodarone is a vasodilator [12], and benzbromarone is effective in lowering uric acid levels, as well as reducing the number of acute gout attacks in patients for whom other treatments are ineffective [13,14]. Although the last two compounds were withdrawn from the market because of their serious side effects, amiodarone is still used. Due to the interesting biological activity of these compounds, it seemed worthwhile to search for new compounds with similar structures in order to identify potentially less toxic compounds, much safer for health and the environment. Other examples of compounds with related structures showing biological activity (Figure 2) can be found in the literature. Compound 1, for example, shows high affinity for adrenergic receptors and possesses antidepressive activity [16]. Derivative 2 inhibits absorption of biogenic amines [15] and 3 decreases blood pressure [17].

**Figure 2.** The structures of halo derivatives of benzofurans: methyl 5-chloro-1-benzofuran-2-carboxylate (1); 5-bromo-3-hydroxy-1-benzofuran-2-yl)(4-methoxyphenyl)methanone (2); 6,7-dichloro-5-[(Z)-[methoxy(oxido)-λ^5-azanylidene](methyl)-λ^4-sulfanyl]-1-benzofuran-2-carboxylic acid (3).

![Chemical structures of halo derivatives of benzofurans](image)

For many years we have been involved in research in the field of synthesis of new biologically active benzofurans. A large number of compounds synthesized by our team contain halogens in their structure and some of them have shown biological activity [19–21], e.g. compounds 4 and 5 (Figure 3).
Figure 3. The structures of methyl 5-bromo-7-hydroxy-6-methoxy-1-benzofuran-2-carboxylate (4); methyl 5-bromo-7-[2-(diethylamino)ethoxy]-6-methoxy-1-benzofuran-2-carboxylate (5).

These two compounds showed significant cytotoxic activity against human cancer cell lines. Additionally, derivative 5 demonstrated antifungal activity. Some 1-(3-amino-2-hydroxypropyl) derivatives of 4,5,6-tribromo-2,3-dihydro-2,2-dimethyl-7-benzofuranol (Figure 4) are effective against Gram-positive bacteria and fungi [20,21]. Our research shows that brominated compounds display lower cytotoxicity than the corresponding precursor compounds before bromination. [20,21].

Figure 4. The general structure 6 of 1-(3-amino-2-hydroxypropyl) derivatives of 4,5,6-tribromo-2,3-dihydro-2,2-dimethyl-7-benzofuranol.

Compound 7 (Figure 5) and its analogues are the topic of a patent application [22]. Compounds of this invention exhibit synergistic antifungal activity in combination with the antifungal compound amiodarone. They are further useful as antifungal agents for the prevention and/or treatment of fungal infections in plants.

Figure 5. The structure of methyl 7-acetyl-5-bromo-3-(bromomethyl)-6-hydroxy-1-benzofuran-2-carboxylate (7).

In light of this information we have decided to continue our research, and thus design and synthesize some new compounds that might show antimicrobial activity (Scheme 1).
2. Results and Discussion

2.1. Chemistry

The chosen starting material was 6-acetyl-5-hydroxy-2-methyl-1-benzofuran-3-carboxylic acid. Compounds I [18,19] and II were obtained by mono- or dimethylation of the starting material with dimethyl sulphate, respectively. Next, the corresponding bromo and/or chloro derivatives were synthesized. As a result, the benzofuran ring of compound I was substituted on C4 and the acetyl group by halogen and we thus obtained methyl 4-bromo-6-(dibromoacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate (III), methyl 4-chloro-6-(chloroacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate (V) and methyl 4-chloro-6-(dichloroacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate (VI). In the case of compound II, only acetyl group halogenations were observed (IV, VII). $^1$H-NMR spectra were obtained for all of the synthesized structures, and for compound VI an X-ray crystal structure was obtained too.

Scheme 1. Method of preparation of compounds I–VII.

2.2. NMR spectra

Analysis of the $^1$H-NMR spectra for the obtained derivatives III, V and VI shows no acetyl group signals, whereas for 6-acetyl-5-hydroxy-2-methyl-3-benzofuranocarboxylic acid we observe a singlet signal for this group for with a chemical shift value of 2.78 ppm. On the other hand, we observed additional signals at 4.74 ppm for compound V, at 6.73 ppm for compound VI, and at 6.72 ppm for compound III, indicating that hydrogens in the acetyl group were substituted by chlorine or bromine. Additionally, for these compounds we do not observe any hydrogen signal for C4, which suggests that
it was substituted by chlorine or bromine, too. We obtained similar $^1$H-NMR spectra for compounds IV, VII.

2.3. X-Ray structure analysis

In order to confirm the structure of VI, the molecular and crystal structure in the solid state was analyzed by single crystal X-ray diffraction. Suitable crystals could only be obtained only for this derivative. A view of the molecular structure together with the atomic numbering scheme is shown in Figure 6 (the drawings were performed with the Mercury program [23]).

![Figure 6. A view of the molecule of VI.](image)

The results indicate that compound VI crystallizes in the monoclinic space group P 2_1/c with one ordered molecule in the asymmetric unit. Selected bond lengths, bond angles and torsion angles are listed in Table 1.

| Bond/Angle | Value   |
|------------|---------|
| O1-C2      | 1.354(2) |
| O1-C8      | 1.371(2) |
| C5-O15     | 1.346(2) |
| C5-C6      | 1.429(3) |
| C6-C16     | 1.463(3) |
| C2-O1-C8   | 107.1(1) |
| C3-C11-O13 | 110.4(2) |
| C6-C16-O17 | 123.3(2) |
| C9-C3-C2-C10 | -178.5(2) |
| C3-C9-C4-C11 | -0.1(3) |
| C7-C6-C5-O15 | -177.3(2) |
| C6-C16-C18-C12 | 81.9(2) |
| C6-C16-C18-C13 | -157.7(2) |

The geometry of the benzofuran ring is comparable to that found in other benzofuran derivatives [19,24–26]. Only the C5-C6 bond length in the benzene seems rather longer due to the substituent at C6 indicating a π-electron delocalization within this fragment of the molecule. The benzofuran moiety is essentially planar with a maximum deviation of 0.017(2)Å for C6. The methoxycarbonyl group is
Molecules 2010, 15

planar to within 0.007Å and makes an angle of 18.65(6)° with plane of the benzofuran system. The C10, O15, C11 atoms are almost coplanar with the benzofuran fragment (the appropriate torsion angles are given in Table 1) and the C16, O17 and C18 atoms are found to be only marginally out of the plane of the two-ring framework [max. deviation of 0.172(3)Å for O17]. Only halogen atoms, Cl2 and Cl3, are considerably out of the mentioned plane (see Table 1). Strong intramolecular hydrogen bonding is present between O15 and O17 atoms (see Figure 6 and Table 2). The angle between the best planes of the benzofuran and the C5/O15/H15/O17/C16/C6 moiety is only 4.37(4)°. Additionally the C11=O12···Cl1-C4 halogen bond [3.018(2)Å] stabilizes the conformation of the molecule.

In the crystal of VI, the packing of the molecules is determined by intermolecular C-H···O hydrogen bonds, Cl···O, C···O interactions and stacking forces. The molecules are linked by C14-H14A···O17 hydrogen bonds forming chains along the a axis, then adjacent chains are connect via C10-H10A···O15 and O1···Cl1 interactions to form layers parallel to the (001) plane (Figure 7).

Figure 7. The interconnections within a layer for VI.

Cohesion between sheets results in Cl···O, C···O interactions and stacking forces. The geometric parameters of all intra- and intermolecular interactions are given in Table 2.

Table 2. Intra- and intermolecular interactions in crystals of VI (Å, deg).

| D-H···A          | D-H  | H···A | D···A  | <(D-H···A) |
|------------------|------|-------|--------|-----------|
| O15-H15···O17    | 0.82 | 1.86  | 2.580(2)| 146       |
| C10-H10A···O15i  | 0.96 | 2.82  | 3.758(3)| 165       |
| C14-H14A···O17ii | 0.96 | 2.66  | 3.470(3)| 142       |
| O12···Cl1i       |      |       | 3.018(2)|           |
| O1···Cl1i        |      |       | 2.995(1)|           |
| C2···O12ii       |      |       | 3.122(3)|           |
| C3···O15iii      |      |       | 3.457(2)|           |
| C16···O15iii     |      |       | 3.238(3)|           |

Symmetry codes: (i) -x+1, y+1/2, -z+1/2; (ii) x+1, y, z; (iii) x, -y+1/2, z+1/2.
2.4. Antimicrobial activity

All the synthesized 6-acetyl-5-hydroxy-2-methyl-3-benzofuranocarboxylic acid derivatives were tested for antimicrobial activity. The microorganisms used in this study included Gram-positive cocci, Gram-negative rods and yeasts. Compounds III, IV, VI were active against Gram-positive cocci: *Staphylococcus aureus* NCTC 4163, *Staphylococcus aureus* ATCC 25923, *Staphylococcus aureus* ATCC 6538, *Staphylococcus aureus* ATCC 29213, *Staphylococcus epidermidis* ATCC 12228, *Bacillus subtilis* ATCC 6633, *Bacillus cereus* ATCC 11778, *Micrococcus luteus* ATCC 9341, *Micrococcus luteus* ATCC 10240. Compounds III, VI showed antifungal activity against *Candida albicans* ATCC 10231, *Candida albicans* ATCC 90028 and *Candida parapsilosis* ATCC 22019. The results are summarized in Table 3.

Table 3. Antimicrobial activity of derivatives III, IV, VI: diameter of the growth inhibition zone.

| Compound strain | Growth inhibition zones in mm (MIC values) | Ciprofloxacin | Fluconazole |
|-----------------|------------------------------------------|---------------|-------------|
|                 | III | IV | VI | nt |
| *S. aureus* NCTC 4163 | 12 (200) | 12 (50) | 12 (100) | 26 (0.5) | nt |
| *S. aureus* ATCC 25923 | 12 (200) | 13 (50) | 12 (200) | 26 (0.5) | nt |
| *S. aureus* ATCC 6538 | 12 (200) | 14 (50) | 12 (100) | 28 (0.5) | nt |
| *S. aureus* ATCC 29213 | 12 (200) | 13 (50) | 12 (100) | 22 (0.5) | nt |
| *S. epidermidis* ATCC 12228 | 12 (100) | 14 (50) | 13 (100) | 30 (0.5) | nt |
| *B. subtilis* ATCC 6633 | 12 (100) | 13 (50) | 13 (100) | 40 (<0.125) | nt |
| *B. cereus* ATCC 11778 | 12 (100) | 15 (50) | 12 (100) | 20 (1) | nt |
| *E. hirae* ATCC 10541 | - (> 400) | - (200) | - (400) | - (4) | nt |
| *M. luteus* ATCC 9341 | 12 (400) | 15 (100) | 12 (200) | 22 (2) | nt |
| *M. luteus* ATCC 10240 | 12 (100) | 15 (50) | 12 (100) | 24 (1) | nt |
| *E. coli* ATCC 10538 | na | na | na | 34 (<0.125) | nt |
| *E. coli* ATCC 25922 | na | na | na | 35 (<0.125) | nt |
| *E. coli* NCTC 8196 | na | na | na | 35 (<0.125) | nt |
| *P. vulgaris* NCTC 4635 | na | na | na | 36 (<0.125) | nt |
| *P. aeruginosa* ATCC 15442 | na | na | na | 25 (0.5) | nt |
| *P. aeruginosa* NCTC 6749 | na | na | na | 26 (0.5) | nt |
| *P. aeruginosa* ATCC 27853 | na | na | na | 23 (1) | nt |
| *B. bronchiseptica* ATCC 4617 | na | na | na | 31 (1) | nt |
| *C. albicans* ATCC 10231 | 12 (100) | na | 13 (100) | nt | 22 (1) |
| *C. albicans* ATCC 90028 | 12 (100) | na | 12 (100) | nt | 32 (1) |
| *C. parapsilosis* ATCC 22019 | 13 (100) | na | 14 (100) | nt | 22 (2) |

na - no activity in disc diffusion test; - denotes lack of a growth inhibition zone; nt – not tested.

Unsubstituted esters I, II showed no microbiological activity. The change of microbiological activity appears when a halogen is introduced into a benzofuran structure. Derivatives in which an acetyl group hydrogen was substituted by one halogen (V, VII) were inactive, in contrast to derivatives in which two acetyl group hydrogens were substituted by halogens (III, IV, VI). These compounds were active against Gram-positive cocci. Additionally, derivatives containing a halogen in the aromatic ring (III, VI) showed antifungal activity (Table 3).

3. Experimental

3.1. General

Melting points were determined in a capillary in Electrothermal 9100 apparatus and are uncorrected. The proton nuclear magnetic resonance spectra (1H-NMR) were recorded in CDCl3 on a
Molecules 2010, 15

Varian UNITY-plus 300 spectrometer operating at 300 MHz. Chemical shift values are expressed in ppm (parts per million) in relation to tetramethylsilane as an internal standard. Mass spectral ESI (Electrospray Ionization) measurements were carried out on a Mariner PE Biosystems instrument with TOF detector. The spectra were obtained in the positive ion mode with a declustering potential 140–300 V. Elemental analyses were recorded with CHN model 2400 Perkin-Elmer. Chromatographic columns were filled with Merck Kieselgel 0.05–0.2 mm reinst (70–325 mesh ASTM) silica gel. Reactions were monitored by TLC on silica gel (plates with fluorescent indicator 254 nm, layer thickness 0.2 mm, Kieselgel G., Merck), using chloroform-methanol 98:2 and 95:5 as eluents.

Methyl 6-acetyl-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate (I). A mixture of 6-acetyl-5-hydroxy-2-methyl-1-benzofuran-3-carboxylic acid (0.02 mole), K₂CO₃ (0.02 mole) and (CH₃O)₂SO₂ (0.02 mole) in acetone (30 mL) was refluxed for 5 h. When the reaction was complete, the mixture was filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel, eluent: chloroform. Yield: 87%; m.p. 170–171 °C; ¹H-NMR δ (ppm): 12.17 (s, 1H, OH), 7.76 (s, 1H, C7-H), 7.46 (s, 1H, C4-H), 3.93 (s, 3H, COOCH₃), 2.78 (s, 3H, COCH₃), 2.67 (s, 3H, CH₃); Anal. Calc. for C₁₃H₁₂O₅: 62.90% C; 4.87% H; found: 62.87% C, 4.87% H; ESI MS m/z: 247.1, 248.8 (100%).

Methyl 6-acetyl-5-methoxy-2-methyl-1-benzofuran-3-carboxylate (II). A mixture of 6-acetyl-5-hydroxy-2-methyl-1-benzofuran-3-carboxylic acid (0.02 mole), K₂CO₃ (0.02 mole) and excess (CH₃O)₂SO₂ (0.06 mole) in acetone (30 mL) was refluxed for 10 h. When the reaction was complete, the boiling mixture was filtered and the solvent was evaporated. The residue was purified by column chromatography on silica gel, eluent: chloroform. Yield: 78%; m.p. 118–119 °C; ¹H-NMR δ (ppm): 7.83 (s, 1H, C7-H), 7.48 (s, 1H, C4-H), 3.87 (s, 3H, COOCH₃), 3.95 (s, 3H, OCH₃), 2.76 (s, 3H, COCH₃), 2.65 (s, 3H, CH₃); Anal. Calc. for C₁₄H₁₄O₅: 64.12% C; 5.38% H; found 64.19% C; 5.39% H.

3.2 General procedure for synthesis of bromo derivatives of esters I and II

The appropriate ester I or II (0.02 mole) was dissolved in CHCl₃ (20 mL) then a solution of bromine (0.04 mole) in CHCl₃ (10 mL) was added dropwise with stirring for 0.5 h. Stirring was continued for 8 h at room temperature. When the reaction was complete the solvent was evaporated. The residue was purified by column chromatography on silica gel, eluent: chloroform.

Methyl 4-bromo-6-(dibromoacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate (III). Yield: 77%; m.p. 149–150 °C; ¹H-NMR δ (ppm): 11.98(s, 1H, OH), 8.00 (s, 1H, C7-H), 6.72 (s, 1H, COCHBr₂), 3.95 (s, 3H, COOCH₃), 2.63 (s, 3H, CH₃); Anal. Calc. for C₁₃H₉O₅Br₃: 32.20% C; 1.87% H; found 32.38% C; 2.09% H; ESI MS m/z: 506.8:508.7 [M+Na]⁺ (100%).

Methyl 6-(dibromoacetyl)-5-methoxy-2-methyl-1-benzofuran-3-carboxylate (IV). Yield: 78%; m.p. 135–138 °C; ¹H-NMR δ (ppm): 7.95 (s, 1H, C7-H), 7.54 (s, 1H, C4-H), 7.22 (s, 1H, COCHBr₂), 4.05 (s, 3H, COOCH₃), 3.98 (s, 3H, OCH₃), 2.80 (s, 3H, CH₃); Anal. Calc. for C₁₄H₁₂O₅Br₂: 40.03% C; 2.88% H; found 39.94% C; 2.77% H.
3.3. General procedure for synthesis of chloro derivatives of esters I and II

The appropriate ester I or II (0.02 mole) was dissolved in CHCl₃ (20 mL). Next chlorine, obtained in the reaction of KMnO₄ with concentrated HCl, was passed through the solution. When the reaction was complete the solvent was evaporated. The residue was purified by column chromatography on silica gel, eluents: chloroform and chloroform/methanol 100:0.5.

Methyl 4-chloro-6-(chloroacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate (V). Yield: 23%; m.p. 187–188 °C; ¹H-NMR δ (ppm): 12.11 (s, 1H, OH), 7.74 (s, 1H, C7-H), 4.74 (s, 2H, COCH₂Cl), 3.96 (s, 3H, COOCH₃), 2.68 (s, 3H, CH₃); Anal. Calc. for C₁₃H₁₀O₅Cl₂: 49.24% C; 3.18% H; found 49.14% C; 3.24% H; ESI MS m/z: 339.6:341[M+Na]+ (100%).

Methyl 4-chloro-6-(dichloroacetyl)-5-hydroxy-2-methyl-1-benzofuran-3-carboxylate (VI). Yield: 36%; m.p. 171–172 °C; ¹H-NMR δ (ppm): 11.70 (s, 1H, OH), 7.98 (s, 1H, C7-H), 6.73 (s, 1H, COCHCl₂), 3.96 (s, 3H, COOCH₃), 2.68 (s, 3H, CH₃); Anal. Calc. for C₁₃H₉O₅Cl₃: 44.41% C; 2.58% H; found 44.60% C; 2.71% H; ESI MS m/z: 350.8:352.6 [M+H]+ (100%).

Methyl 6-(chloroacetyl)-5-methoxy-2-methyl-1-benzofuran-3-carboxylate (VII). Yield: 54%; m.p. 130–131 °C; ¹H-NMR δ (ppm): 7.69 (s, 1H, C7-H), 7.19 (s, 1H, C4-H), 4.75 (s, 2H, COCH₂Cl), 3.88 (m, 6H, COOCH₃, OCH₃), 2.60 (s, 3H, CH₃); Anal. Calc. for C₁₄H₁₃O₅Cl*2H₂O: 50.53% C; 3.90% H; found 50.60% C; 3.90% H.

3.4. Crystallography

Crystals of VI suitable for X-ray analysis were grown from acetic acid solution by slow evaporation. All details of the measurements, crystal data and structure refinement are given in Table 4. The data were collected on an Oxford Diffraction KM4CCD diffractometer [27] at 293 K, using graphite-monochromated MoKα radiation. The unit cell parameters were determined by least-squares treatment of setting angles of highest-intensity reflections chosen from the whole experiment. Intensity data were corrected for the Lorentz and polarization effects [28]. The structure was solved by direct methods by use the SHELXS97 program [29] and refined by the full-matrix least-squares method with the SHELXL97 program [30]. Two reflections were excluded from the reflection file due to their large \(|F_o|^2-|F_c|^2\) differences. The function \(\Sigma w(|F_o|^2-|F_c|^2)^2\) was minimized with \(w^{-1} = [\sigma^2(F_o)^2+(0.0474P)^2+0.6944P]\), where \(P = (F_o^2+2F_c^2)/3\). All non-hydrogen atoms were refined with anisotropic thermal parameters. The coordinates of the hydrogen atoms were calculated in idealized positions and refined as a riding model with their thermal parameters calculated as 1.2 (1.5 for methyl group) times \(U_{eq}\) of the respective carrier carbon atom. An empirical extinction correction was also applied according to the formula \(F_c’ = kF_c[1+(0.001\chi F_c^2\lambda^3/\sin2\theta)]^{1/4}\) [30], and the extinction coefficient \(\chi\) was equal to 0.008(1). The deposition number CCDC 700768 contains the supplementary crystallographic data of compound VI for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.
Table 4. Crystal data, data collection and structure refinement for compound VI.

| Compound | VI |
|----------|----|
| Empirical formula | C_{13}H_{9}O_{5}Cl_{3} |
| Formula weight | 351.55 |
| T (K) | 293(2) |
| Wavelength (Å) | 0.71073 |
| Crystal system, space group | monoclinic, P 2_1/c |
| Unit cell dimensions |
| a (Å) | 13.0544(3) |
| b (Å) | 15.7053(3) |
| c (Å) | 7.0108(2) |
| β (°) | 104.897(3) |
| Volume (Å³) | 1389.07(6) |
| Z, D_x (Mg/m³) | 4, 1.681 |
| μ (mm⁻¹) | 0.677 |
| F(000) | 712 |
| θ range for data collection (°) | 2.07 – 25.00 |
| hkl range |
| -15 ≤ h (15 |
| -18 (k (18 |
| -8 (l (8 |
| Reflections: |
| collected | 13369 |
| unique (Rint) | 2409(0.019) |
| observed (I > 2(I)) | 2003 |
| Data / restraints / parameters | 2409 / 0 / 191 |
| Absorption correction | multi-scan |
| Goodness-of-fit on F² | 1.055 |
| R(F) (I > 2σ(I)) | 0.0293 |
| wR(F²) (all data) | 0.0895 |
| Max/min. Δρ (e/ Å³) | 0.315 / -0.237 |

3.5. Microbiology

The antimicrobial activity of compounds was tested against a series of microorganisms obtained from the collection of the Department of Pharmaceutical Microbiology, Medical University of Warsaw (Poland), including: Gram-positive cocci: *Staphylococcus aureus* NCTC 4163, *Staphylococcus aureus* ATCC 25923, *Staphylococcus aureus* ATCC 6538, *Staphylococcus aureus* ATCC 29213, *Staphylococcus epidermidis* ATCC 12228, *Bacillus subtilis* ATCC 6633, *Bacillus cereus* ATCC 11778, *Enterococcus hirae* ATCC 10541, *Micrococcus luteus* ATCC 9341, *Micrococcus luteus* ATCC 10240; Gram-negative rods: *Escherichia coli* ATCC 10538, *Escherichia coli* ATCC 25922, *Escherichia coli* NCTC 8196, *Proteus vulgaris* NCTC 4635, *Pseudomonas aeruginosa* ATCC 15442, *Pseudomonas aeruginosa* NCTC 6749, *Pseudomonas aeruginosa* ATCC 27863, *Bordetella bronchiseptica* ATCC 4617 and yeasts: *Candida albicans* ATCC 10231, *Candida albicans* ATCC 90028, *Candida parapsilosis* ATCC 22019.
Antimicrobial activity was examined by the disc-diffusion method and the MIC method under standard conditions using Mueller-Hinton II agar medium (Becton Dickinson) for bacteria or RPMI agar medium (Sigma) with 2% glucose for fungi, according to CLSI guidelines [31,32]. For the disc diffusion assay sterile filter paper discs (9 mm diameter, Whatman No 3 chromatography paper) were wetted with tested compound solutions (in DMSO) to load 400 μg of a given compound per disc. For MIC determinations concentrations of tested compounds in solid medium ranged from 6.25 to 400 μg/mL. The final inoculum, of all microorganisms were 10^4 CFU mL^-1 (colony forming units per mL), except the final inoculum for \textit{E. hirae} ATCC 10541, which was 10^5 CFU mL^-1. The results were read after 18 h (for bacteria) or 24 h (for fungi) of incubation at 35 °C. The results are summarized in Table 3.

4. Conclusions

This study describes the synthesis and preliminary microbiological investigations of some 3-benzofurancarboxylic acid derivatives. Seven derivatives were examined. It was noticed that compounds not possessing halogen in their structure did not show any activity during the experiments, whereas compounds possessing halogens in their structure showed such activity. Halogens were introduced to alkyl substituent as well as to the aromatic ring. Derivatives in which the halogen, without the regard for the kind, was introduced in the aromatic ring, showed better activity, as these compounds displayed both antimicrobial and antifungal activity. Basing on these findings, as well as on results from our earlier investigations, we can confirm that the search for biologically active compounds in the area of halogen derivatives of benzofurans remains an interesting field from the biological point of view.

References

1. Kodama, I.; Kamiya, K.; Toyama, J. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent. \textit{Am. J. Cardiol.} \textbf{1999}, \textit{84}, 20R-28R.

2. Cui, B.; Chai, H.; Reutrakul, V.; Farnsworth, N.R.; Cordell, G.A.; Pezzutto, J.M.; Kinghorn, A.D. Novel cytotoxic 1H-cyclopenta[b]-benzofuran lignans from \textit{Aglaia elliptica}. \textit{Tetrahedron} \textbf{1997}, \textit{53}, 17625-17632.

3. Lee, S.K.; Cui, B.; Mehta, R.R.; Kinghorn, A.D.; Pezzutto, J.M. Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from \textit{Aglaia elliptica}. \textit{Chem. Biol. Interact.} \textbf{1998}, \textit{115}, 215-228.

4. Hwang, B.Y.; Su, B.N.; Chai, H.; Mi, Q.; Kardono, L.B.; Afriastini, J.J.; Riswan, S.; Santarsiero, B.D.; Mesecar, A.D.; Wild, R.; Fairchild, C.R.; Vite, G.D.; Rose, W.C.; Farnsworth, N.R.; Cordell, G.A.; Pezzutto, J.M.; Swanson, S.M.; Kinghorn, A.D. Silvestrol and episilvestrol, potential anticancer rocaiglate derivatives from Aglaia silvestris. \textit{J. Org. Chem.} \textbf{2004}, \textit{69}, 3350-3358.

5. Hattori, M.; Hada, S.; Watahiki, A.; Ihara, H.; Shu, Y.Z.; Kakiuchi, N.; Mizuno, T.; Namba, T. Studies on dental caries prevention by traditional medicines. X. Antibacterial action of phenolic components from mace against \textit{Streptococcus mutans}. \textit{Chem. Pharm. Bull. (Tokyo)} \textbf{1986}, \textit{34}, 3885-3893.
6. Erber, S.; Ringshandl, R.; von Angerer, E. 2-Phenylbenzo[b]furans: relationship between structure, estrogen receptor affinity and cytostatic activity against mammary tumor cells. Anticancer Drug Des. 1991, 6, 417-426.

7. Hayakawa, I.; Shioya, R.; Agatsuma, T.; Furukawa, H.; Naruto, S.; Sugano, Y. 4-Hydroxy-3-methyl-6-phenylbenzofuran-2-carboxylic acid ethyl ester derivatives as potent anti-tumor agents. Bioorg. Med. Chem. Lett. 2004, 14, 455-458.

8. Courchesne, W.E. Characterization of novel, broad-based fungicidal activity for antiarrhythmic drug amiodarone. J. Pharmacol. Exp. Ther. 2002, 300, 195-199.

9. Courchesne, W.E.; Ozturk, S. Amiodarone induces a caffeine-inhibited, MID1-dependent rise in free cytoplasmic calcium in Saccharomyces cerevisiae. Mol. Microbiol. 2003, 47, 223-234.

10. Nattel, S.; Singh, B.N.; Evolution, mechanisms, and classifications of antiarrhythmic drugs: Focus on class III actions. Am. J. Cardiol. 1999, 84, 11R-19R.

11. Gill, J.; Heel, R.C.; Fitton, A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992, 43, 69-110.

12. Pizzichini, M.; Aleo, M.F.; Marcolongo, R.; Marinello, E. The mechanism of benziodarone activity. Quad Sclavo Diagn 1982, 18, 203-208.

13. Heel, R.C.; Brogden, R.N.; Speight, T.M.; Avery, G.S. Benz bromarone: A review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. Drugs 1977, 14, 349-366.

14. Masbernard, A.; Giudicelli, C.P. ‘Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. S. Afr. Med. J. 1981, 59, 701-706.

15. Repolles, M.J.; Pubill, C.F.; Cabeza, L.L.; Carbo, B.M.; Cerda, R.J.A.; Negrie, R.C. Benzofuran, dihydrobenzofuran, dihydrobenzopyran and benzopyran derivatives as antidepressant agents. Spanish Patent ES2131020 A1, 1999.

16. Graves, A.P.; Brenk, R.; Shoichet, B.K. Decoys for docking. J. Med. Chem. 2005, 48, 3714-3728.

17. Matsuda, S.; Ishii, M.; Kitajiri, N.; Yahara, I.; Harada, H.; Yonetani, Y. Antihypertensive property of a novel uricosuric diuretic, S-8666, in rats. Drug Dev. Res. 1989, 17, 207-217.

18. Zawadowski, T.; Kossakowski, J.; Rechowicz, P. Synthesis of 2-methyl-5-hydroxy-6-acetylbenzofuran-3-carboxylic acid and its derivatives. Roczniki Chemii Ann. Soc. Chim. Polonorum. 1977, 51, 159-162.

19. Kossakowski, J.; Ostrowska, K.; Hejchman, E.; Wolska, I. Synthesis and structural characterization of derivatives of 2- and 3-benzo[b]furan carboxylic acids with potential cytotoxic activity. Il Farmaco 2005, 60, 519-527.

20. Kossakowski, J.; Ostrowska, K. Synthesis of new derivatives of 2,3-dihydro-7-benzo[b]furanol with potential pharmacological activity. Acta Pol. Pharm. 2006, 63, 271-275.

21. Kossakowski, J.; Ostrowska, K.; Struga M.; Stefańska J. Synthesis of new derivatives of 2,2-dimethyl-2,3-dihydro-7-benzo[b]furanol with potential antimicrobial activity. Med. Chem. Res. 2009, 18, 555-565.

22. Courchesne, W.E.; Hejchman, E.; Maciejewska, D.; Kossakowski, J.; Ostrowska, K. Antifungal compounds. US Pat. Appl. 20090270496 (A1), 29 October 2009.
23. Macrae, C.F.; Edgington, P.R.; McCabe, P.; Pidcock, E.; Shields, G.P.; Taylor, R.; Towler, M.; van de Streek, J. Mercury: Visualization and analysis of crystal structures, J. Appl. Cryst. 2006, 39, 453-457.

24. Bachechi, F.; Coiro, V.M.; Delfini, M.; Settimj, G. Structure of 2-acetyl-3-aminobenzofuran. Acta Cryst. 1988, C44, 1449-1451.

25. Gould, R.O.; Guest, M.F.; Joswig, J.O.; Palmer, M.H.; Parsons, S. Ethyl 3-Hydroxybenzo(b)furan-2-carboxylate. Acta Cryst. 1998, C54, 1951-1954.

26. Thiruvalluvar, A.; Silvarani, S.; Vadivelu, A.; Sithik, Ali K.; Venkataraman, V.R. 2-Acetylbenzo[b]furan. Acta Cryst. 2003, E59, o395.

27. CrysAlisCCD, CCD data collection GUI, version 1.171.32.5; Oxford Diffraction Poland, 2007.

28. CrysAlisRED, CCD data reduction GUI, version 1.171.32.5; Oxford Diffraction Poland, 2007.

29. Sheldrick G.M. Phase annealing in SHELXL90: Direct methods for larger structures. Acta Crystallogr. 1990, A46, 467-473.

30. Sheldrick G.M. SHELXL97, Program for the Refinement of Crystal Structures; University of Göttingen: Göttingen, Germany, 1997.

31. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disc Susceptibility Tests; Approved Standard M2-A9; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2006.

32. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard M7-A7; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2006.

Sample Availability: Samples of the compounds are available from the authors.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).